We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$103M
Cap. Flow %
9.71%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 64.11%
2 Technology 8.21%
3 Consumer Discretionary 1.63%
4 Industrials 1.41%
5 Communication Services 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
51
Travere Therapeutics
TVTX
$5.2B
$5.1M 0.48%
+250,000
New +$3.98M
LRMR icon
52
Larimar Therapeutics
LRMR
$397M
$5.1M 0.48%
396,787
+133,323
+51% +$1.55M
ASND icon
53
Ascendis Pharma A/S
ASND
$16B
$5.08M 0.48%
34,373
+1,800
+6% +$247K
QURE icon
54
uniQure
QURE
$3.03B
$4.96M 0.47%
110,000
-91,107
-45% -$5.38M
XCUR icon
55
Exicure
XCUR
$10.2M
$4.64M 0.44%
12,667
-9,232
-42% -$3.35M
ZYME icon
56
Zymeworks
ZYME
$1.61B
$4.2M 0.39%
116,310
-90,520
-44% -$3.33M
ORGS
57
DELISTED
Orgenesis Inc. Common Stock
ORGS
$4.05M 0.38%
66,577
-44,379
-40% -$2.69M
ARYAU
58
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$4M 0.38%
200,000
– –
ARYBU
59
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$3.48M 0.33%
+300,000
New +$3.3M
CPRX
60
DELISTED
Catalyst Pharmaceutical
CPRX
$3.38M 0.32%
+730,557
New +$3.28M
GRTX
61
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.35M 0.32%
469,245
-6,432
-1% -$68.3K
ENPH icon
62
Enphase Energy
ENPH
$4.96B
$3.33M 0.31%
+70,000
New +$3.35M
SNDX icon
63
Syndax Pharmaceuticals
SNDX
$1.69B
$3.26M 0.31%
220,000
+151,866
+223% +$2.31M
WVE icon
64
Wave Life Sciences
WVE
$1.09B
$3.05M 0.29%
+293,000
New +$2.76M
CGEN icon
65
Compugen
CGEN
$222M
$3M 0.28%
+200,000
New +$2.7M
KALV
66
DELISTED
KalVista Pharmaceuticals
KALV
$2.91M 0.27%
240,140
– –
PRGO icon
67
Perrigo
PRGO
$1.4B
$2.76M 0.26%
+50,000
New +$2.63M
SLNO
68
DELISTED
Soleno Therapeutics
SLNO
$2.74M 0.26%
+82,245
New +$3.56M
IMVT icon
69
Immunovant
IMVT
$7.93B
$2.56M 0.24%
105,000
+85,968
+452% +$1.84M
ARGX icon
70
argenx
ARGX
$53.4B
$2.31M 0.22%
10,265
– –
AKUS
71
DELISTED
Akouos Inc
AKUS
$2.25M 0.21%
+100,000
New +$2.23M
AKBA icon
72
Akebia Therapeutics
AKBA
$354M
$2.1M 0.2%
+155,000
New +$1.6M
CRBP icon
73
CALL
Corbus Pharmaceuticals
CRBP
$166M
$2M 0.19%
+7,950
New +$1.61M
CYPH
74
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.84M 0.17%
88,000
+28,000
+47% +$600K
LITS
75
Lite Strategy Inc
LITS
$32.8M
$1.69M 0.16%
+20,500
New +$1.24M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $103M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.